HVTN Co-PI Glenda Gray appointed new president of South African Medical Research Council

March 24, 2014 Comments off

HVTN’s Co-PI Glenda Gray is the new President of South Africa’s MRC, effective 4/1/2014. For the full story, please see Fred Hutchinson’s Cancer Center’s News Release.

Categories: Uncategorized

A New Grant Cycle for the HVTN – Network Awarded New 7-Year Grant by NIH

February 21, 2014 Comments off

Adi Ferrara

January 2014 marks the beginning of a new grant cycle for the HVTN. Since our founding in 1999, we have grown in size, and the depth and breadth of our trials have increased significantly, as did the complexity of the questions we ask.1 As the HIV vaccine field moved beyond single product testing into combination regimens, the HVTN helped advance this field by testing a wide variety of products and schedules, and leveraging its ability to obtain data through standardized methods and compare it across multiple trials. Along the way, the HVTN also helped advance the knowledge in fields as varied as social-behavioral science, statistics, immunology, and HIV vaccinology. We have done so through our own research and through collaborating with numerous scientists across various academic institutions who are conducting ancillary studies utilizing our data and specimens. Read more…

Categories: Uncategorized

Members of the HVTN’s Executive Management Team

February 21, 2014 Comments off
Categories: HVTN Members

Beyond Blood: What are Mucosal and Genital Study Specimens Revealing So Far?

February 22, 2014 Comments off

Tracey Day and Eva Chung

HIV vaccines that induce robust immune responses in genital and rectal tissues may provide the best defense against sexually transmitted HIV infections. To monitor immune responses induced by candidate HIV vaccines in these tissues, the HVTN has developed procedures to collect and process a variety of mucosal and genital specimens.1 These efforts are enabling a wide range of analyses, beyond those measured in peripheral blood, to be conducted in conjunction with HVTN trials. Read more…

Categories: Uncategorized

AIDS Vaccine 2013 Report: “Vaccine Induced Antibody Responses in HVTN 505, A Phase 2b HIV-1 Efficacy Trial”

February 22, 2014 Comments off

Adi Ferrara and Cecilia Morgan

In the HVTN’s efficacy trials, the questions the Network’s researchers ask, and the answers they are able to get, are more detailed and complex than earlier phase trials allow. Among other aspects, these questions delve deeper into highly specific immune responses generated by study products, trying to tease apart which responses might correlate with reduced risk of infection and, possibly, with vaccine efficacy. Read more…

Categories: Uncategorized

Immunogenicity Assessments Made in HVTN Trials

February 22, 2014 Comments off

This illustration describes the wide range of immune response readouts that can be obtained from peripheral blood (top panel) and mucosal and genital specimens (bottom panel). Vaccines that generate favorable responses in genital and mucosal tissues may provide the best protection against sexually transmitted HIV infection and thus, the HVTN has developed an array of procedures to examine vaccine responses elicited in these compartments. A multitude of assays have also been developed to probe both descriptive and functional aspects of vaccine-induced humoral and cellular responses.

From collection of clinical samples through specimen processing and immunogenicity measures to data analyses, the HVTN clinical sites, processing labs, endpoints labs, and statistical data management center provide a wealth of capabilities for evaluation and cross-trial comparison of candidate HIV vaccines. Two articles in this issue (see Beyond Blood and AIDS Vaccine 2013 Report) highlight how HVTN researchers have already begun to capitalize on the sophisticated analyses that these capabilities provide, and demonstrate that the Network is poised to deliver the data needed to accelerate the search for a safe and globally effective preventive HIV vaccine. Read more…

Categories: Uncategorized

The HVTN Welcomes New Sites

February 21, 2014 Comments off

Adi Ferrara

With a new grant cycle, the HVTN welcomes new sites to the Network, though in reality not all these sites are new to HVTN work — several of them have worked with the Network before as protocol-specific sites. In the United States, 1 site joins the Network, while 6 sites join internationally. Over the next 24 months, up to 20 additional sites will become part of the Uhambo effort in southern Africa (see HVTN in Southern Africa). Read more…

Categories: Uncategorized

HVTN in Southern Africa: A Journey of Hope

February 21, 2014 Comments off

Adi Ferrara

The word Uhambo means either “opportunity” (in Shona) or “journey” (in Xhosa), but in both southern African languages the meaning sums up the feelings and hopes that accompany an exciting new effort for the HVTN. “The end of AIDS is possible and within our grasp,” said Salim Abdool Karim,1 the president of the South African Medical Research Council (MRC) and the director of the Centre for the AIDS Programme of Research in South Africa (CAPRISA). In October 2013, the HVTN, MRC, and their partners officially launched Uhambo, a “massive grand endeavor” as HVTN PI Dr. Larry Corey called it,2 a multinational effort to bring an HIV vaccine to licensure in southern Africa, and the rest of the world. Read more…

Categories: Uncategorized
Follow

Get every new post delivered to your Inbox.